Skip to main content
. 2018 May 16;16(1):931–939. doi: 10.3892/ol.2018.8713

Figure 1.

Figure 1.

KFX increases PPAR-γ mRNA expression and decreases the viability of SGC-7901 cells. (A) SGC-7901 cells were treated with KFX at different concentrations (0, 0.25, 0.5 and 2.5 mg/ml) for 12 and 24 h, and the PPAR-γ mRNA level was analyzed by reverse transcription-polymerase chain reaction. The histogram presents the quantitative analysis of PPAR-γ mRNA level, and the data are expressed as fold over control group; n=6 for each group. Data are presented as the mean ± standard error of the mean. *P<0.05 compared with KFX (0 mg/ml) treatment for 12 h; #P<0.05 compared with KFX (0 mg/ml) treatment for 24 h. (B) The anti-proliferative effect of KFX was investigated using an MTT assay. SGC-7901 cells were treated with different dosages of KFX (0, 0.05, 0.15, 0.25, 0.5 and 2.0 mg/ml) for 12 and 24 h; n=6 for each group. Data are presented as the mean ± standard error of the mean. *P<0.05 compared with KFX (0 mg/ml) treatment for 12 h; #P<0.05 compared with KFX (0 mg/ml) treatment for 24 h. KFX, Kangfuxin; PPAR-γ, peroxisome proliferator-activated receptor γ.